Lumos Diagnostics Holdings (ASX:LDX) has received Medicare reimbursement recognition for the company's point-of-care respiratory test, FebriDx, from US Medicare administrative contractor (MAC) National Government Services, at a rate of $41.38 per test, according to a Friday filing with the Australian bourse.
The company has now achieved coverage from all seven MACs, and will now work with them to establish a formal written policy, the filing said.
Shares of the company rose 13% in recent Friday trade.